The Potential Role of Factor VIIa in Transfusion Medicine

Therapy with high doses of recombinant factor VIIa (rFVIIa) is effective in promoting hemostasis in hemophiliacs. There is also some evidence to support the idea that this agent can enhance hemostasis in patients with platelet function defects, thrombocytopenia and liver failure, as well as in persons without a preexisting bleeding disorder. Because of this hemostatic effect in a wide range of clinical settings, it is possible that rFVIIa could serve as a substitute or supplement to the transfusion of blood products.

Duke Scholars

Author Maureane Hoffman Pathology